CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 557 enrolled
Drug / intervention
insulin degludec/liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01952145
NCT01952145Phase 3Completed
CompareCT.gov

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)

Novo Nordisk A/S·interventional·Posted Sep 27, 2013·Updated Jan 3, 2019

In Brief

A Phase 3 clinical trial evaluating insulin degludec/liraglutide and insulin glargine for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 557 participants across 91 sites in 10 countries.

Detailed Summary

This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Australia, Greece, Hungary, Mexico, Russia, Slovakia, South Africa, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 27, 2013
Enrollment StartSep 20, 2013
Primary CompletionNov 4, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.8 years ago

Interventions

insulin degludec/liraglutidedrug

Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.

insulin glarginedrug

Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.